COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Fecha
2020-06-29Autor
Fürstenau, Moritz
Langerbeins, Petra
De Silva, Nisha
Fink, Anna Maria
Robrecht, Sandra
von Tresckow, Julia
Simon, Florian
Hohloch, Karin
Droogendijk, Jolanda
van der Klift, Marjolein
van der Spek, Ellen
Illmer, Thomas
Schöttker, Björn
Fischer, Kirsten
Wendtner, Clemens M.
Tausch, Eugen
Stilgenbauer, Stephan
Niemann, Carsten U.
Gregor, Michael
Kater, Arnon P.
Hallek, Michael
Eichhorst, Barbara
Documentos PDF
Resumen en idioma extranjero
With more than 5 million proven infections and more than 300,000 associated deaths worldwide [1], the SARS-CoV-2 pandemic poses unprecedented challenges to health-care professionals and especially those treating and caring for patients with malignant hematological diseases. These patients often have multiple different risk factors for severe infections [2]. Chronic lymphocytic leukemia (CLL) is the most common form of leukemia and infections are a known contributor to morbidity and mortality due to a disease-inherent immunodeficiency [3, 4]. Considering this multifactorial immune defect, it appears conceivable that patients with CLL are more susceptible to infections with SARS-CoV-2 and more likely to develop severe courses of the associated respiratory disease COVID-19, especially when under additional immunosuppression by chemoimmunotherapy (CIT). Few case reports on COVID-19 in CLL patients from countries with suspected different prevalence rates of COVID-19 have been published so far. The publications report a patient after first-line treatment with single-agent chlorambucil, a case series with four treatment-naive CLL patients, a case series of eight patients on Bruton tyrosine kinase (BTK) inhibitors and most recently a heterogeneously treated population of four patients from the Hospital Clinic of Barcelona [5,6,7,8]. While it has been hypothesized that the BTK inhibitor ibrutinib might have protective effects against COVID-19 by attenuating hyperinflammatory responses, there is currently no data on COVID-19 in patients receiving venetoclax-based treatments [7, 9]. A recent study has suggested a reduction of CLL-inherent immunosuppression after successful treatment with venetoclax-based regimens [10]. In light of these data we sought to determine the incidence, severity, and possible risk factors of COVID-19 cases in a well-defined cohort of patients with CLL receiving venetoclax-based combination treatments as first-line therapy in a prospective clinical trial.
Palabras clave
venetoclax; leukemiaEnlace al recurso
https://www.nature.com/articles/s41375-020-0941-7Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.